Maternal and Neonatal Outcomes in Nulliparous Participants Undergoing Labor Induction by Cervical Ripening Method.


Journal

American journal of perinatology
ISSN: 1098-8785
Titre abrégé: Am J Perinatol
Pays: United States
ID NLM: 8405212

Informations de publication

Date de publication:
07 2023
Historique:
pmc-release: 05 02 2023
medline: 12 7 2023
pubmed: 6 8 2021
entrez: 5 8 2021
Statut: ppublish

Résumé

This study aimed to evaluate maternal and neonatal outcomes by method of cervical ripening for labor induction among low-risk nulliparous individuals. This is a secondary analysis of a multicenter randomized trial of labor induction at 39 weeks versus expectant management in low-risk nulliparous participants. Participants undergoing cervical ripening for labor induction in either group were included. Participants were excluded for preripening membrane rupture, abruption, chorioamnionitis, fetal demise, or cervical dilation ≥3.5 cm. Cervical ripening was defined by the initial method used: prostaglandin only (PGE; referent), Foley with concurrent prostaglandin (Foley-PGE), Foley only (Foley), and Foley with concurrent oxytocin (Foley-oxytocin). Coprimary outcomes were adverse maternal and neonatal composites. Secondary outcomes included cesarean delivery and length of labor and delivery (L&D) stay. Multivariable analysis was used to adjust for patient characteristics. Of 6,106 participants included in the trial, 2,376 (38.9%) met criteria for this analysis. Of these, 1,247 (52.4%) had cervical ripening with PGE, 290 (12.2%) had Foley-PGE, 385 (16.2%) had Foley, and 454 (19.1%) had Foley-oxytocin. The maternal composite outcome was similar among participants who received Foley-PGE (24.1%, adjusted relative risk [aRR] = 1.21, 95% confidence interval [CI]: 0.96-1.52), Foley (21.3%, aRR = 1.16, 95% CI: 0.92-1.45), or Foley-oxytocin (19.4%, aRR = 1.04, 95% CI: 0.83-1.29), compared with PGE (19.7%). The neonatal composite outcome was less frequent in participants who received the Foley-PGE (2.4%, aRR = 0.35, 95% CI: 0.16-0.75) or Foley (3.6%, aRR = 0.51, 95% CI: 0.29-0.89) but did not reach statistical significance for participants who received Foley-oxytocin (4.6%, aRR = 0.63, 95% CI: 0.40-1.01) compared with PGE only (6.8%). Participants who received Foley-PGE or Foley-oxytocin had a shorter L&D stay (adjusted mean difference = -1.97 hours, 95% CI: -3.45 to -0.49 and -5.92 hours, 95% CI: -7.07 to -4.77, respectively), compared with PGE. In term low-risk nulliparous participants, Foley alone or concurrent with PGE is associated with a lower risk of adverse neonatal outcomes than with PGE alone. Length of L&D stay was the shortest with concurrent Foley-oxytocin. · Adverse maternal outcomes are similar among different methods of cervical ripening in low-risk women.. · Adverse neonatal outcomes are less frequent with use of Foley alone or in combination with PGE.. · The use of Foley alone, or in combination with other agents, appears to be beneficial..

Identifiants

pubmed: 34352922
doi: 10.1055/s-0041-1732379
pmc: PMC8817048
mid: NIHMS1733114
doi:

Substances chimiques

Oxytocin 50-56-6
Oxytocics 0
Dinoprostone K7Q1JQR04M

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1061-1070

Subventions

Organisme : NICHD NIH HHS
ID : U10 HD040500
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD034116
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040560
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD053097
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD040485
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD034116
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD068258
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD040560
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD036801
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD027869
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD068268
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD040544
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087230
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD027915
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087192
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040544
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD034208
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040512
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD027869
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD027915
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD068282
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040545
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040485
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD068268
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD034208
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD068258
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD053097
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040500
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD068282
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD040512
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD040545
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR001873
Pays : United States

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None declared.

Références

Arch Gynecol Obstet. 2010 Mar;281(3):473-7
pubmed: 19488776
BMC Pregnancy Childbirth. 2013 Jan 29;13:25
pubmed: 23356673
N Engl J Med. 2018 Aug 09;379(6):513-523
pubmed: 30089070
Obstet Gynecol. 2016 Dec;128(6):1357-1364
pubmed: 27824758
Obstet Gynecol. 1997 Mar;89(3):387-91
pubmed: 9052591
Am J Obstet Gynecol. 2004 Jun;190(6):1689-94; discussion 1694-6
pubmed: 15284771
Am J Obstet Gynecol. 1997 Sep;177(3):612-8
pubmed: 9322632
Am J Obstet Gynecol. 2010 Nov;203(5):418-29
pubmed: 20605133
Acta Obstet Gynecol Scand. 2011 Sep;90(9):997-1004
pubmed: 21615714
Obstet Gynecol. 2008 Jun;111(6):1320-6
pubmed: 18515515
J Matern Fetal Neonatal Med. 2003 Apr;13(4):254-9
pubmed: 12854927
Int J Gynaecol Obstet. 2004 Sep;86(3):398-400
pubmed: 15325864
Am J Obstet Gynecol. 2018 Sep;219(3):294.e1-294.e6
pubmed: 29763609
Obstet Gynecol. 2018 Jan;131(1):23-29
pubmed: 29215514
Sao Paulo Med J. 2003 May 5;121(3):102-6
pubmed: 12920470
Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1108-12
pubmed: 10561627
Am J Obstet Gynecol. 2008 Sep;199(3):305.e1-5
pubmed: 18771993
Rev Bras Ginecol Obstet. 2013 Feb;35(2):60-5
pubmed: 23412004
BJOG. 2011 May;118(6):647-54
pubmed: 21332637
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001233
pubmed: 22419277
BJOG. 2016 Feb;123(3):346-54
pubmed: 26538408
Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):55-60
pubmed: 9914578
Natl Vital Stat Rep. 2013 Jun 28;62(1):1-69, 72
pubmed: 24974591

Auteurs

Maria Andrikopoulou (M)

Department of Obstetrics and Gynecology, Columbia University, New York, New York.

Elisa T Bushman (ET)

Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama.

Madeline M Rice (MM)

The George Washington University Biostatistics Center, Washington, District of Columbia.

William A Grobman (WA)

Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois.

Uma M Reddy (UM)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.

Robert M Silver (RM)

Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah.

Yasser Y El-Sayed (YY)

Department of Obstetrics and Gynecology, Stanford University, Stanford, California.

Dwight J Rouse (DJ)

Department of Obstetrics and Gynecology, Brown University, Providence, Rhode Island.

George R Saade (GR)

Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas.

John M Thorp (JM)

Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

Suneet P Chauhan (SP)

Department of Obstetrics and Gynecology, University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas.

Maged M Costantine (MM)

Department of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio.

Edward K Chien (EK)

Department of Obstetrics and Gynecology, MetroHealth Medical Center-Case Western Reserve University, Cleveland, Ohio.

Brian M Casey (BM)

Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas.

Sindhu K Srinivas (SK)

Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.

Geeta K Swamy (GK)

Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina.

Hyagriv N Simhan (HN)

Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH